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mechanisms of tissue injury may exist. Antibodies against minor
histocompatibility antigens develop in association with cGVHD,
suggesting a role for B cells. We therefore began a clinical trial of
speciﬁc anti-B-cell therapy with rituxan for steroid-refractory
cGVHD. Methods: Subjects had steroid-refractory ( 0.5 mg/kg
prednisone each day for 4 weeks), clinically extensive cGVHD on
stable doses of immunosuppressants. Rituxan (375 mg/m2/week 
4) was followed by a second course for nonresponders or partial
responders 4 weeks later. All patients underwent thorough oral,
ocular, rheumatologic, and dermatologic examinations by subspe-
cialists before and 8 weeks after rituxan therapy. A validated symp-
tom scale was administered before and after rituxan therapy. Re-
sults: 16 patients (median age, 42.5 years) were treated, 15 of
whom were on steroids (4 alone, 7 with 1 immunosuppresant, and
4 with 2 immunosuppressants). One patient was on tacrolimus
alone. End-organ involvement included skin (in 13 patients), eye
(in 8 patients), musculoskeletal (in 8 patients), and oral mucosa (in
5 patients). Six patients received 1 and 10 patients received 2
4-week courses of rituxan at a mean of 13.7 months (range, 2.9–82
months) from cGVHD diagnosis and 24.6 months from transplan-
tation (range, 8.5–114.6 months). There were 5 grade 3 adverse
events (3 cases of gastroenteritis, 1 case of hepatitis B reactivation,
and 1 case of conjunctivitis) and 1 infusion reaction. Eight weeks
after starting rituxan, CD19 B cells were undetectable in all
peripheral blood samples, median serum IgG levels fell by 19.8%,
and IgM levels fell by 33%. Median follow-up was 160 days.
Objective responses were noted in 10 patients (62.5%, all skin/
musculoskeletal responses), and one patient had progressive cuta-
neous cGVHD. There was 1 cGVHD ﬂare after a partial response
and 1 malignant relapse. The median reduction in clinical cutane-
ous involvement was 52%, and the median reduction in the rheu-
matologic VAS pain score was 87.5%. Mean symptom scores
improved in 7 patients (6 of whom had clinical responses), were
unchanged in 7 patients, and worsened in 2 patients. As a result of
cGVHD responses, prednisone doses were decreased in 11 patients
and unchanged in 4 patients (median dose reduction, 50%). At this
time, all patients remain on systemic immunosuppression. Con-
clusions: Rituxan is safe in patients with cGVHD and is active
against cutaneous and musculoskeletal cGVHD. B-cell immunity
contributes to at least some of the clinical manifestations of
cGVHD.
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HYPERACUTE GVHD: ANALYSIS OF RISK FACTORS, CLINICAL MANIFES-
TATIONS, AND OUTCOMES
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We evaluated the clinical characteristics and risk factors for
hyperacute graft-versus-host disease (GVHD) in 815 consecutive
patients transplanted at M.D. Anderson Cancer Center between
January 1998 and September 2002. Our deﬁnition of hyperacute
GVHD included all patients with a diagnosis of GVHD within 14
days after allogeneic bone marrow or peripheral blood stem cell
transplantation (PSCT). Of 381 patients presenting with clinical
evidence of acute GVHD, 22% (n  83) occurred within 14 days
posttransplantation (early GVHD), and were all biopsy-proven.
Grade I GVHD occurred in 12% of these patients, grade II in
53%, grade III in 13%, and grade IV in 22%. The proportion of
grade II-IV GVHD in this group was signiﬁcantly higher (88%)
than in the 298 patients presenting with GVHD between days 15
and 100 posttransplantation (64%) (P  .001). The majority of
patients with early GVHD had skin involvement (89%), followed
by gastrointestinal (43%), and liver GVHD (19%). Skin involve-
ment was signiﬁcantly more common (89% vs 76%; P  .01), and
more severe (stage III or IV 63% vs 32%; P  .001) in the early
GVHD group. Signiﬁcantly factors on univariate analysis included
a graft from a mismatched (MM) related donor (HR  4.4; P 
.001) or a matched unrelated donor (MUD) (HR  2.4; P .001)
vs a graft from a matched related donor, and myeloablative pre-
parative regimen with or without total body irradiation (HR 2.5;
P  .001). These effects remained signiﬁcant when evaluated in a
multivariate model. Donor’s age  40 years was associated with a
marginally signiﬁcant lower rate of early GVHD (HR  0.6; P 
.05), and there was a trend toward increased rates for patients
receiving sex-mismatched grafts, patients transplanted for solid
tumors, and those having received more than 5 chemotherapy
regimens before transplantation. There was no difference in the
distribution of CD34 or CD3 cells infused. All-cause mortality
rate was signiﬁcantly higher within 6 months posttransplantation
for patients with early GVHD (HR  2.2; P  .001) compared
with all other patients or to patients developing acute GVHD after
day 14 (HR  1.6; P  .009). Acute GVHD death rate was also
signiﬁcantly higher (HR  2.3; P  .007). Hyperacute GVHD
occurs in a substantial proportion of patients undergoing HSC
transplant, even before neutrophil engraftment. Skin involvement,
grades 3–4 GVHD, and higher mortality are common features of
this syndrome.
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We previously showed that low levels of day-14 CD3 T and NK
(CD56) cells donor chimerism predicted graft rejection, whereas
high levels of day-28 CD3 T-cell donor chimerism predicted acute
graft-versus-host disease (GVHD) after HCT with nonmyeloab-
lative conditioning. Here we investigate whether assessing chimer-
ism levels among CD4 T cells and CD8 T cells, and also the
absolute number of lymphocyte subsets of donor and host origins,
would lend greater precision to our initial observations. We ana-
lyzed data from 157 patients receiving HCT after conditioning
with 2 Gy TBI / ﬂudarabine as treatment for AML (n  22),
ALL (n  4), CML (n  13), CLL (n  19), MDS (n  26), MM
(n  24), NHL (n  30), HD (n  14), RCC (n  4), and WASP
deﬁciency (n  1). Postgrafting immunosuppression included
MMF and CSP. A total of 97 patients received grafts from HLA-
identical siblings, and 60 patients received grafts from HLA-
matched unrelated donors. Lymphocyte subsets were isolated from
peripheral blood by ﬂow cytometry on days 14, 28, and 42. The
proportion of cells of donor origin (chimerism levels) were assessed
by VNTR-PCR and quantiﬁed by phosphor imaging. Eighteen
patients (11%) had graft rejection. Day-14 donor chimerism lev-
els  50% among CD3 T (P .0007), CD4 T (P .03), and NK
cells (P.003) but not CD8 T cells predicted graft rejection. High
absolute numbers of CD3 T (P .002) and NK cells (P  .002) of
host origin on day 14 were each associated with increased risks of
graft rejection when treated as continuous linear variables. Grades
2, 3, and 4 acute GVHD were seen in 40%, 9%, and 5% of
patients, respectively. High donor chimerism levels on day 14
among CD3 T (P  .02), CD4 T (P .03), and CD8 T cells (P
.02) but not NK cells were each associated with increased risks of
grades 2–4 acute GVHD. High absolute numbers of CD4 T (P
.04) and CD8 T cells (P .04) of donor origin on days 14–42
were each associated with increased risks of grade 2–4 acute
GVHD when treated as continuous linear variables, whereas high
donor CD3 T (P  .002), CD8 T (P  .006), and NK cell (P 
.002) chimerism levels from days 14–42 were associated with
decreased risks of relapse. No statistically signiﬁcant correlations
between absolute numbers of donor cells and risks of relapse were
found. These data suggest that assessing CD3, CD4, CD8, and NK
cell donor chimerism levels and determining absolute numbers of
CD3 and NK cells of host and donor origins are useful for pre-
dicting HCT outcomes after nonmyeloablative conditioning.
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